摘要
目的探讨术前FolFox新辅助化疗对大肠癌Sm ad4表达的影响。方法对进展期大肠癌54例患者,术前Fol-Fox新辅助化疗+根治术治疗15例(FolFox新辅助化疗组),术前5-FU静脉化疗+根治术治疗18例(5-FU化疗组)及仅行根治手术21例(非化疗组)。应用免疫组化SP技术对3组大肠癌标本进行Sm ad4检测,比较Sm ad4表达阳性率。结果Smad4的表达阳性率非化疗组19.0%(4/21)、术前5-FU静脉化疗组61.1%(11/18)、术前FolFox新辅助化疗组93.3%(14/15)。差异有统计学意义(P<0.05)。结论术前FolFox新辅助化疗可使进展期大肠癌组织中Sm ad4表达明显增高,可作为有效的一种治疗进展期大肠癌的辅助化疗手段。
Objective To investigate the effects of preoperative FolFox neoadjuvant chemotherapy on the expression of Smad4 in eolorectal carcinoma. Methods Fifteen cases of advanced eolorectal carcinoma were treated by preoperative FolFox neoadjuvant chemotherapy （the FolFox neoadjuvant chemotherapy group） ,18 cases by 5-FU chemotherapy （the 5-FU chemotherapy group） and 21 cases by operation （the control group）. The expression of Smad4 was detected by immunohistoehemieal SP method. Results Among the three groups, the expression level of Smad4 gradually increased （P 〈 0.05）. The positive expressions of Smad4 in the three groups Were 19.0 % （4/21） in the control group,61.1% （ 11/18） in the 5-FU chemotherapy group and 93.3% （ 14/15 ） in the FolFox neoadjuvant chemotherapy group respectively. The difference was significant （ P 〈 0. 05 ）. Conclusion Preoperative FolFox neoadjuvant chemotherapy could induce high level of Smad4 expression, which could be an effective chemotherapy.
出处
《实用医院临床杂志》
2011年第1期37-39,共3页
Practical Journal of Clinical Medicine
关键词
术前
化疗
大肠癌
SMAD4
Preoperative
Chemotherapy
Colorectal carcinoma
Smad4
